TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration
Status:
Terminated
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
VERTACL will investigate whether a triple therapy, Avastin®, half fluence verteporfin
photodynamic therapy (PDT), and triamcinolone acetonide-preservative free (TAC- PF), results
in improved 12-month vision outcome compared to Avastin® alone in participants with
neovascular AMD.